Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Effect and Mechanism of Sancao Lichang Decoction on Diarrhea- Predominant Irritable Bowel Syndrome by Regulating Tlr4/Myd88/Nf-Κb Pathway

Author(s): Peng Zhang, Ying Ma, Zheng Wang and Decai Tang*

Volume 26, Issue 13, 2023

Published on: 05 April, 2023

Page: [2372 - 2379] Pages: 8

DOI: 10.2174/1386207326666230301104248

Price: $65

Abstract

Objective: To evaluate the effect of Sancao Lichang decoction as traditional Chinese medicine on diarrhea-predominant irritable bowel syndrome (IBS-D) and TLR4/MyD88/NF-κB pathway.

Background: Traditional Chinese medicine has made significant progress in preventing and treating irritable bowel syndrome, and its efficacy has been validated by clinical practice. Sancao Lichang decoction is an empirical prescription developed by professor Tang Decai that has been used for many years to treat chronic diarrhoea with good curative effec. Still, its mechanism of action on IBS-D is unknown.

Methods: The study sample of Fifty SD rats was randomly divided into a blank group, model group, low-dose group, medium-dose group, and high-dose group (n = 10). The IBS-D rat models were established by restraining stress method and acetic acid enema. After different treatments, defecation frequency, fecal water content (FWC), serum IL-6 and TNF-α contents, and protein level of TLR4/MyD88/NF-κB in colon tissues were detected separately.

Results: The indexes of rats in each group were significantly different. The increase in body weight in the medium-dose and high-dose groups was significantly higher than that in the model group (p < 0.05). Compared with the model group, the medium and high dose groups had lower diarrhea frequency, FWC, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) (p < 0.05). The expression levels of TLR4, MyD88, and NF-κB protein in the colon of the three groups treated with Sancao-Lichan decoction were significantly lower than those in the model group (p < 0.01). After different treatments, the colonic mucosa of rats in each group was stained with HE, which proved that the structural damage of colonic mucosa was improved after treatment with Sancao Lichang decoction, and the improvement effect was dose-dependent.

Conclusion: Sancao Lichang decoction may reduce IBS-D by inhibiting TLR4/MyD88/NF-κB pathway, inhibiting the inflammatory response, and improving intestinal mucosal barrier function.

« Previous Next »
Graphical Abstract

[1]
Weaver, K.R.; Melkus, G.D.E.; Henderson, W.A. Irritable bowel syndrome. Am. J. Nurs., 2017, 117(6), 48-55.
[http://dx.doi.org/10.1097/01.NAJ.0000520253.57459.01] [PMID: 28541989]
[2]
Vahedi, H.; Ansari, R.; Mir-Nasseri, M.; Jafari, E. Irritable bowel syndrome: A review article. Middle East J. Dig. Dis., 2010, 2(2), 66-77.
[PMID: 25197516]
[3]
Oka, P.; Parr, H.; Barberio, B.; Black, C.J.; Savarino, E.V.; Ford, A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 2020, 5(10), 908-917.
[http://dx.doi.org/10.1016/S2468-1253(20)30217-X] [PMID: 32702295]
[4]
Black, C.J.; Ford, A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol., 2020, 17(8), 473-486.
[http://dx.doi.org/10.1038/s41575-020-0286-8] [PMID: 32296140]
[5]
Liu, Y-L.; Liu, J-S. Chinese expert consensus of irritable bowel syndrome in 2020. Chin. Med. J., 2021, 40, 803-818.
[6]
Liu, Y.L.; Liu, J.S. Irritable bowel syndrome in China: A review on the epidemiology, diagnosis, and management. Chin. Med. J., 2021, 134(12), 1396-1401.
[http://dx.doi.org/10.1097/CM9.0000000000001550] [PMID: 34074848]
[7]
Review, A. Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome JAMA, 2021, 325(9), 865-877.
[http://dx.doi.org/10.1001/jama.2020.22532] [PMID: 33651094]
[8]
Lacy, B.E.; Pimentel, M.; Brenner, D.M.; Chey, W.D.; Keefer, L.A.; Long, M.D.; Moshiree, B. ACG clinical guideline: Management of irritable bowel syndrome. Am. J. Gastroenterol., 2021, 116(1), 17-44.
[http://dx.doi.org/10.14309/ajg.0000000000001036] [PMID: 33315591]
[9]
Chen, G.; Xie, X.; Peng, C. Treatment of irritable bowel syndrome by Chinese medicine: A review. Chin. J. Integr. Med., 2021, 1-8.
[http://dx.doi.org/10.1007/s11655-021-3521-4] [PMID: 34546535]
[10]
Singh, R.K.; Mehta, S.; Sharma, A.K. Ethnobotany, pharmacological activities and bioavailability studies on “King of Bitters” (Kalmegh): A review (2010-2020). Comb. Chem. High Throughput Screen., 2022, 25(5), 788-807.
[http://dx.doi.org/10.2174/1386207324666210310140611] [PMID: 33745423]
[11]
Mehta, S.; Sharma, A.K.; Singh, R.K. Advances in ethnobotany, synthetic phytochemistry and pharmacology of endangered herb Picrorhiza kurroa (Kutki): A comprehensive review (2010-2020). Mini Rev. Med. Chem., 2021, 21(19), 2976-2995.
[http://dx.doi.org/10.2174/1389557521666210401090028] [PMID: 33797375]
[12]
Mehta, S.; Sharma, A.K.; Singh, R.K. Therapeutic journey of Andrographis paniculata (burm.f.) nees from natural to synthetic and nanoformulations. Mini Rev. Med. Chem., 2021, 21(12), 1556-1577.
[http://dx.doi.org/10.2174/1389557521666210315162354] [PMID: 33719961]
[13]
Zhao, Y.; Kumar, D.; Prasad, D.N.; Singh, R.K.; Ma, Y. Morphoanatomic, physicochemical, and phytochemical standardization with HPTLC fingerprinting of aerial parts of Aerva lanata (Linn) Juss ex Schult. J. Trad. Chin. Med.Sci., 2015, 2(1), 39-44.
[http://dx.doi.org/10.1016/j.jtcms.2014.12.002]
[14]
Mehta, S.; Sharma, A.K.; Singh, R.K. Pharmacological activities and molecular mechanisms of pure and crude extract of Andrographis paniculata: An update. Phytomed. Plus, 2021, 1(4), 100085.
[http://dx.doi.org/10.1016/j.phyplu.2021.100085]
[15]
Ji, L.; Zhao, X.; Zhang, Y.; Zhao, P.; Gong, R.; Li, F.; Huang, H. Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial. Medicine, 2022, 101(9), e28895.
[http://dx.doi.org/10.1097/MD.0000000000028895]
[16]
Wang, Y.; Fan, H.; Qi, X.; Lai, Y.; Yan, Z.; Li, B.; Tang, M.; Huang, D.; Li, Z.; Chen, H.; Zhu, Q.; Luo, C.; Chen, X.; Fen, J.; Jiang, Z.; Zheng, L.; Liu, X.; Tang, Q.; Zuo, D.; Ye, J.; Yang, Y.; Huang, H.; Tang, Z.; Lu, W.; Xiao, J. Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms? A randomized controlled trial. Complement. Ther. Med., 2018, 40, 95-105.
[http://dx.doi.org/10.1016/j.ctim.2018.07.002] [PMID: 30219477]
[17]
Liu, W. Clinical study on Sini decoction and tongxie yaofang in treating liver qi and spleen-type irritable bowel syndrome. Syst. Med., 2019, 4, 121-122.
[18]
Yang, H.; Liu, X.; Peng, W.; Chen, R.; Chen, Y. Lipi Guben decoction in treating diarrheal irritable bowel syndrome. Medicine, 2021, 100(3), e23887.
[http://dx.doi.org/10.1097/MD.0000000000023887] [PMID: 33545956]
[19]
Xiangyu, D.; Fan, Z.; Decai, T. Introduction of Tang Decai’s self-made sancao lichang decoction in the treatment of chronic diarrhea. New Chin. Med., 2019, 0(8), 325-327.
[20]
Yang, J.; Shang, B.; Shi, H.; Zhu, S.; Lu, G.; Dai, F. The role of toll-likereceptor 4 and mast cell in the ameliorating effect of electroacupuncture on visceral hypersensitivity in rats. Neurogastroenterol. Motil., 2019, 31(6), e13583-e13587.
[http://dx.doi.org/10.1111/nmo.13583] [PMID: 30916854]
[21]
He, X.; Cui, L.H.; Wang, X.H.; Yan, Z.H.; Li, C.; Gong, S.D.; Zheng, Y.; Luo, Z.; Wang, Y. Modulation of inflammation by toll-like receptor 4/nuclear factor-kappa B in diarrhea-predominant irritable bowel syndrome. Oncotarget, 2017, 8(69), 113957-113965.
[http://dx.doi.org/10.18632/oncotarget.23045] [PMID: 29371960]
[22]
Zhou, T.; Zhang, Y.; Lu, X. Improvement and evaluation of a rat model of chronic restraint stress diarrhea-type irritable bowel syndrome. J. Guangzhou Univ. Trad. Chinese Med., 2018, 35(1), 163-168.
[23]
Zang, K.; Qin, H. Research progress on animal models of post-infection irritable bowel syndrome. Southeast Univ. J., 2016, 35(4), 598-601.
[24]
Scalera, A.; Di Minno, M.N.; Tarantino, G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J. Gastroenterol., 2013, 19(33), 5402-5420.
[http://dx.doi.org/10.3748/wjg.v19.i33.5402] [PMID: 24023483]
[25]
Stogdale, L. Veterinary herbal medicine. Can. Vet. J., 2008, 49(8), 802.
[http://dx.doi.org/10.1016/B978-0-323-02998-8.50024-X]
[26]
Cao, L.; Du, C.; Zhai, X.; Li, J.; Meng, J.; Shao, Y.; Gao, J. Codonopsis pilosula polysaccharide improved spleen deficiency in mice by modulating gut microbiota and energy related metabolisms. Front. Pharmacol., 2022, 13, 862763.
[http://dx.doi.org/10.3389/fphar.2022.862763] [PMID: 35559259]
[27]
Shi, K.; Qu, L.; Lin, X.; Xie, Y.; Tu, J.; Liu, X.; Zhou, Z.; Cao, G.; Li, S.; Liu, Y. Deep-fried atractylodis rhizoma protects against spleen deficiency-induced diarrhea through regulating intestinal inflammatory response and gut microbiota. Int. J. Mol. Sci., 2019, 21(1), 124.
[http://dx.doi.org/10.3390/ijms21010124] [PMID: 31878055]
[28]
Huang, Z.; Wei, C.; Yang, K.; Yu, Z.; Wang, Z.; Hu, H. Aucklandiae Radix and Vladimiriae Radix: A systematic review in ethnopharmacology, phytochemistry and pharmacology. J. Ethnopharmacol., 2021, 280, 114372.
[http://dx.doi.org/10.1016/j.jep.2021.114372] [PMID: 34186101]
[29]
Na, J.R.; Kim, E.; Na, C.S.; Kim, S. Citric acid-enriched extract of Ripe Prunus mume (Siebold) Siebold & Zucc. induces laxative effects by regulating the expression of aquaporin 3 and prostaglandin e 2 in rats with loperamide-induced constipation. J. Med. Food, 2022, 25(1), 12-23.
[http://dx.doi.org/10.1089/jmf.2021.K.0138] [PMID: 35029511]
[30]
Beatty, J.K.; Bhargava, A.; Buret, A.G. Post-infectious irritable bowel syndrome: Mechanistic insights into chronic disturbances following enteric infection. World J. Gastroenterol., 2014, 20(14), 3976-3985.
[http://dx.doi.org/10.3748/wjg.v20.i14.3976] [PMID: 24744587]
[31]
Katinios, G.; Casado-Bedmar, M.; Walter, S.A.; Vicario, M.; González-Castro, A.M.; Bednarska, O.; Söderholm, J.D.; Hjortswang, H.; Keita, Å.V. Increased colonic epithelial permeability and mucosal eosinophilia in ulcerative colitis in remission compared with irritable bowel syndrome and health. Inflamm. Bowel Dis., 2020, 26(7), 974-984.
[http://dx.doi.org/10.1093/ibd/izz328] [PMID: 31944236]
[32]
Wang, J.P.; Dong, L.N.; Wang, M.; Guo, J.; Zhao, Y.Q. MiR-146a regulates the development of ulcerative colitis via mediating the TLR4/MyD88/NF-κB signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(5), 2151-2157.
[PMID: 30915760]
[33]
Qiao, C.; Yang, L.; Wan, J.; Liu, X.; Pang, C.; You, W.; Zhao, G. Long noncoding RNA ANRIL contributes to the development of ulcerative colitis by miR-323b-5p/TLR4/MyD88/NF-κB pathway. Biochem. Biophys. Res. Commun., 2019, 508(1), 217-224.
[http://dx.doi.org/10.1016/j.bbrc.2018.11.100] [PMID: 30477744]
[34]
Zhang, Y.; Wang, X.; Wang, S.; Yan, Z.; Li, C.; Zheng, Y.; Cui, L. Heat shock protein 27 regulates the inflammatory response of intestinal epithelial cells by the nuclear factor-κb pathway. Dig. Dis. Sci., 2020, 65(12), 3514-3520.
[http://dx.doi.org/10.1007/s10620-020-06074-z] [PMID: 32078087]
[35]
Zhang, C.; Huang, Y.; Li, P.; Chen, X.; Liu, F.; Hou, Q. Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction. BMC Compl. Med. Ther., 2020, 20(1), 279-284.
[http://dx.doi.org/10.1186/s12906-020-03059-3] [PMID: 32928188]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy